Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feedernewsroom.regeneron.com
Regeneron Pharmaceuticals Inc. News Releases
Get the latest updates from Regeneron Pharmaceuticals Inc. News Releases directly as they happen.
Follow now 143 followers
Latest posts
Last updated about 22 hours ago
Regeneron Reports Fourth Quarter and Full Year 2025 Financial and Operating Results
about 23 hours ago
Fourth quarter 2025 revenues increased 3% to $3.9 billion versus fourth quarter...
Nation’s Top 40 High School Scientists to Compete for $1.8 Million in Awards at the Prestigious Regeneron Science Talent Search
10 days ago
The Regeneron Science Talent Search Honors America’s Brightest Young Scientists Advancing Discovery...
Regeneron to Report Fourth Quarter and Full Year 2025 Financial and Operating Results and Host Conference Call and Webcast on January 30, 2026
29 days ago
TARRYTOWN, N.Y. , Jan. 02, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc...
Dupixent® (dupilumab) Approved in Japan for Children Aged 6 to 11 Years with Bronchial Asthma
about 1 month ago
Approval based on global Phase 3 program in children demonstrating Dupixent significantly...
Regeneron Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference
about 1 month ago
TARRYTOWN, N.Y. , Dec. 22, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc...
Lynozyfic™ (linvoseltamab) Monotherapy in Newly Diagnosed Multiple Myeloma (NDMM) Shows Impressive Responses, Supporting Rationale as a Potential Foundation in Frontline Treatment
about 2 months ago
All three dose groups (50 mg, 100 mg and 200 mg) showed...
Regeneron and Tessera Therapeutics to Jointly Develop TSRA-196, an Investigational Gene Editing Therapy for Alpha-1 Antitrypsin Deficiency (AATD)
2 months ago
TSRA-196 is a potential one-time treatment to precisely correct the genetic mutation...
Dupixent® (dupilumab) Approved as the First Targeted Medicine in the European Union (EU) in Over a Decade for Chronic Spontaneous Urticaria (CSU)
2 months ago
Approval based on Phase 3 trials showing Dupixent significantly reduced itch and...
EYLEA HD® (aflibercept) Injection 8 mg Approved by FDA for the Treatment of Macular Edema Following Retinal Vein Occlusion (RVO) and for Monthly Dosing Across Approved Indications
2 months ago
First and only FDA-approved treatment for RVO indicated for up to every...
Libtayo® (cemiplimab) Approved in the European Union as First and Only Immunotherapy for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with High Risk of Recurrence after Surgery and Radiation
2 months ago
Approval based on results of landmark Phase 3 C-POST trial that show...
Regeneron Highlights Progress at American Society of Hematology (ASH), with Updated Data in Multiple Myeloma, Lymphoma and Paroxysmal Nocturnal Hemoglobinuria Programs
3 months ago
Oral presentation of Lynozyfic™ (linvoseltamab-gcpt) data in newly diagnosed multiple myeloma from...
Phase 2 Trials Demonstrating Antithrombotic Effect of Two Novel Regeneron Factor XI Antibodies Presented at American Heart Association Scientific Sessions and Published in The Lancet
3 months ago
Proof-of-concept trials confirm robust anti-clotting effects for Regeneron’s two mechanistically-distinct antibodies against...